Brink's Progress on NCR Atleos Deal

By Tamara Parker • Thursday, October 08 10:53 • Permanent Link

Brink’s said the U.K.’s Competition and Markets Authority has accepted in principle a proposed remedy tied to its planned acquisition of NCR Atleos, clearing a key hurdle in the review process.

The remedy centers on divesting NoteMachine/Testlink UK, a move Brink’s said would address the U.K.-specific concerns raised early in the review. The company said the sale process is already progressing and that it is engaged with multiple prospective buyers.

Brink’s said the divestiture was already reflected in the financial metrics it had previously disclosed and would not affect the $200 million in annual run-rate cost synergies it expects to achieve within three years of closing.

The acquisition remains on track to close early in the first quarter of 2027. Brink’s said the proposed remedy does not change that timeline.

Brink’s operates in 51 countries and serves customers in more than 100 countries. As a result of these announcements, the company's shares have moved -1.38% on the market, and are now trading at a price of $102.07. For the full picture, make sure to review BRINKS CO's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.